View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jacob Mekhael
  • Jacob Mekhael

Galapagos GLPG3667 phase 2 hits topline in DM, but misses in SLE

Galapagos announced the topline results from 2 phase 2 studies evaluating the efficacy and safety of GLPG3667 (TYK2 inhibitor) in dermatomyositis (DM, GALARISSO study) and active systemic lupus erythematosus (SLE, GALACELA study). The GALARISSO study in DM met its primary endpoint showing a 14.26 delta on the TIS measure at 24 weeks, which compares favourably to brepocitinib (TYK2/JAK1 inhibitor) in our view. In the GALACELA study in SLE patients, primary endpoint at 32 weeks was not met, but fi...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, N...

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

 PRESS RELEASE

Galapagos Announces Topline Results from Two Phase 3-Enabling Studies ...

Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile ...

 PRESS RELEASE

Galapagos maakt topline resultaten bekend van twee fase 3-enabling stu...

Galapagos maakt topline resultaten bekend van twee fase 3-enabling studies met selectieve TYK2-remmer GLPG3667 bij dermatomyositis en systemische lupus erythematodes GLPG3667 bereikte het primaire eindpunt in de dermatomyositis-studie en toonde een statistisch significant klinisch voordeel en betekenisvolle verbeteringen aan op secundaire eindpunten van ziekteactiviteit in vergelijking met placebo In de studie naar systemische lupus erythematodes leverde GLPG3667 numerieke verbeteringen op voor verschillende secundaire eindpunten in vergelijking met placebo, maar bereikte het geen statisti...

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 202...

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th American Society of Hematol...

 PRESS RELEASE

Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH...

Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025 Hoge percentages complete respons en minimale residuele ziekte (MRD)-negativiteit, met duurzame responsen, bij hoog-risico mantelcellymfoom (MCL) met GLPG5101, een verse, early-memory verrijkte CAR T-celtherapie met een vein-to-vein-tijd van 7 dagen Mechelen, België; 8 december 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde nieuwe en geüpdatete fase 2-gegevens aan uit de lopende ATALANTA-1-studie met haar CD19 CAR T-celtherapiekandidaat GLPG5101, tijdens een mondelinge presentatie (#662) op de 67s...

Guy Sips ... (+3)
  • Guy Sips
  • Michiel Declercq
  • Wim Hoste

Local Champions Mid Cap Conference Book 11.12.2025

This conference book is your guide to our annual Local Champions Mid Cap Conference set to take place on Thursday, 11 December 2025 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or attend small group sessions with the top management and/or IR of the following companies: BARCO | BEKAERT | DECEUNINCK | DEME | EVS | IBA | JENSEN GROUP | MATERIALISE | ONTEX | PROXIMUS | RECTICEL | XFAB

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aalberts: Big step forward in disposal programme. Belfius: No sale of stake to private investors, no sell down of BNP Paribas stake either. CM.com: Bird withdraws takeover proposal. Recticel: Acquisition of a 76% stake in Miclar Group. Theon International: c.€150m rights issue

Wim Hoste
  • Wim Hoste

Recticel FIRST LOOK: Acquisition of Miclar Group, upgrade to Accumulat...

With the acquisition of a 76% stake in Miclar Group, Recticel further strengthens its insulated panels business, which today consists of the businesses acquired via Rex and Trimo. The deal value looks very reasonable at 5.7x EV/EBITDA24. We have updated our forecasts resulting in a 7% increase in our 2026 EBITDA estimate. Recticel still has significant firepower for additional acquisitions and we would expect the company to continue to hunt for mid-sized acquisitions that further enlarge positio...

Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Galapagos Receives Transparency Notifications from Bank of America

Galapagos Receives Transparency Notifications from Bank of America Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on November 18 and November 19, 2025, from Bank of America Corporation indicating that it positively crossed the threshold of 5% of Galapagos’ voting rights on November 12, 2025 following an acquisition of Galapagos’ voting rights and equivalent financial instrumen...

 PRESS RELEASE

Galapagos ontvangt transparantieverklaringen van Bank of America

Galapagos ontvangt transparantieverklaringen van Bank of America Mechelen, België; 26 november 2025, 07:30 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft transparantieverklaringen ontvangen van Bank of America. Overeenkomstig de Belgische transparantiewetgeving1 ontving Galapagos op 18 en 19 november 2025 transparantieverklaringen van Bank of America Corporation. Daaruit blijkt dat Bank of America op 12 november 2025 de drempel van 5% van de stemrechten in Galapagos positief heeft overschreden na een verwerving van stemrechten en daarmee gelijkgestelde fin...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: 3Q mixed, NIBC M&A good value for money. Adyen: CMD highlights – confident on long-term growth Belgian Telecoms: Digi Belgium raises €104.5m in capital, after €80m capital increase in July. CM.com: Raises €5m through private placement. Recticel: Peer Rockwool's 3Q25 trading update. Zabka: Potential bidder for Carrefour Romania. Events Calendar

Jacob Mekhael
  • Jacob Mekhael

Galapagos 9M25 conference call feedback

Galapagos reported 9M25 results and hosted a conference call to discuss its results. We provide the key takeaways from the call in this note.

Martial Descoutures
  • Martial Descoutures
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Lynn Hautekeete
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : AED BB, COFB BB, GLPG NA, JEN BB, SOLB BB, VGP BB, SHU...

: AED BB, COFB BB, GLPG NA, JEN BB, SOLB BB, VGP BB, SHUR BB, CTPNV NA, IMCD NA, SYENS BB

Martial Descoutures
  • Martial Descoutures
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch